cbdMD, Inc.
YCBD · AMEX
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | -0.01 | 0.15 |
| FCF Yield | -3.96% | -27.60% | -14.55% | -1.80% |
| EV / EBITDA | -10.06 | -0.93 | -6.83 | -40.62 |
| Quality | ||||
| ROIC | -98.64% | -72.38% | 103.15% | -15.85% |
| Gross Margin | 61.57% | 62.01% | 63.09% | 67.41% |
| Cash Conversion Ratio | 0.10 | 0.19 | 0.21 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.05% | -18.41% | -5.45% | 23.43% |
| Free Cash Flow Growth | 86.02% | 70.62% | 4.74% | -37.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.79 | -0.09 | 0.12 | 0.92 |
| Interest Coverage | -108.10 | 0.00 | 0.00 | -678.05 |
| Efficiency | ||||
| Inventory Turnover | 3.17 | 2.26 | 3.07 | 2.89 |
| Cash Conversion Cycle | 58.61 | 103.75 | 76.92 | 60.58 |